COMPANY PROFILE

Omniome

Explore full profile

Developer of an innovative new DNA sequencing platform

San Diego, United StatesFounded 2013Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Omniome

Omniome operates at the cutting edge of DNA sequencing technology, leveraging advancements in nanotechnology and genomics to deliver unparalleled solutions. The company primarily serves research institutions, healthcare providers, and biotech firms that require precise and efficient DNA sequencing capabilities. Operating in the rapidly growing genomics market, Omniome's business model revolves around the development and sale of high-performance sequencing instruments and consumables. Revenue is generated through the sale of these products, as well as through service contracts and maintenance agreements. The company is known for its collaborative environment, bringing together a team of skilled scientists and engineers dedicated to pushing the boundaries of what's possible in DNA sequencing.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2013
Headquarters: San Diego, United States
Employees: 2
Open positions: None listed
Dealroom signal: 59.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Innovation Management, Developer Tools, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Pay Per Result, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jul 2021	$800M	$800M	Pacific Biosciences	—
SERIES COther financing	Jan 2020	$60M	$240M	ARCH Venture Partners · Decheng Capital · Biomatics Capital Partners · Domain Associates	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Omniome website traffic

Latest recorded traffic for Omniome is 230 monthly website visits, down 69.7% over the last three months. Omniome's team declined 88.9% over the past year.

Latest monthly visits230 3-month web change-69.7% 1-year team growth-88.9%

Monthly website visitsOct 2017–Sep 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GEGencoveDedicated to making genomic data more accessible and interpretable through molecular and software tools	New York City, United States	Operational	14	$26M	$40M
BSBIA SeparationsA worldwide provider of solutions for biopharmaceutical companies	Wilmington, United States	Acquired
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
GVGenomic VisionBiotechnology company developing genetic tests and research tools for the life sciences sector	Bagneux, France	Closed
BIBiocerosCell lines development from DNA sequences	Ølstykke, Denmark	Acquired
ACAcceraBiotechnology company engaged in the discovery and development of therapeutic drugs for neurodegenerative diseases	Denver, United States	Operational
ALAlectorCombining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel	San Francisco, United States	Operational